Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01876446 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Small Cell Lung Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Pegylated Irinotecan
OTHER: Pharmacological Study

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]
[object Object]